Pancreatic Cancer Research

ResearcherDüsseldorf University HospitalActive in the last 2 years

Sami Alexander Safi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9874-9225; OpenAlex author ID A5005092473, A5112077079. Sources: OpenAlex.

Their work

Papers
10 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 3 papers · 2023: none · 2024: none · 2025: none · 2026: 3 papers

Papers 10

  1. Standardizing computed tomographic assessment of the mesopancreas in pancreatic cancer patients. First author DOI 10.1007/s00261-026-05486-1↗
  2. Correction: Standardizing computed tomographic assessment of the mesopancreas in pancreatic cancer patients. First author DOI 10.1007/s00261-026-05656-1↗
  3. The Mesopancreas remains at risk in primary resectable pancreatic cancer patients: time to reappraise resectability criteria? Last author DOI 10.1016/j.ctarc.2026.101176↗
  4. N, LNR or LODDS: Which Is the Most Appropriate Lymph Node Classification Scheme for Patients with Radically Resected Pancreatic Cancer? First author DOI 10.3390/cancers14071834↗
  5. Clinicopathological and Prognostic Value of Survivin Expression in Surgically Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14143494↗
  6. Quality of Life in Patients with Pancreatic Cancer before and during the COVID-19 Pandemic. Co-author DOI 10.3390/ijerph19063731↗
  7. Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival. Co-author DOI 10.1016/j.pan.2021.02.024↗
  8. Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers14010068↗
  9. HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer. Co-author DOI 10.15252/embj.2019102808↗
  10. Stromal heterogeneity in pancreatic cancer and chronic pancreatitis. Co-author DOI 10.1016/j.pan.2018.05.004↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wolfram Trudo Knoefel · 10 shared papers, 2018–2026 · strength 1.68
  2. Iréne Esposito · 9 shared papers, 2018–2026 · strength 1.54
  3. A. Alexander · 4 shared papers, 2022–2026 · strength 0.96
  4. Farid Ziayee · 4 shared papers, 2021–2026 · strength 0.94
  5. Lena Haeberle · 3 shared papers, 2026 · strength 0.81
  6. Stephan O. David · 3 shared papers, 2026 · strength 0.81
  7. Lena Häberle · 5 shared papers, 2018–2022 · strength 0.58
  8. Alexander Rehders · 4 shared papers, 2021–2022 · strength 0.54
  9. Andreas H. Krieg · 3 shared papers, 2021–2022 · strength 0.42
  10. Tom Luedde · 3 shared papers, 2021–2022 · strength 0.40
  11. Christian Vay · 2 shared papers, 2022 · strength 0.29
  12. Dimitrios Prassas · 1 shared paper, 2022 · strength 0.15
  13. Anna Melissa Schlitter · 1 shared paper, 2018 · strength 0.09
  14. Mert Erkan · 1 shared paper, 2018 · strength 0.09
  15. Mark Kalisz · 1 shared paper, 2020 · strength 0.09
  16. Eva Cristina Vaquero · 1 shared paper, 2020 · strength 0.09
  17. Jorge P. Ferrer · 1 shared paper, 2020 · strength 0.09
  18. Francisco X. Real · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.